Exelixis
EXEL
$49.29
Share price
-5.75%
Change (1 day)
55.31%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total assets
Total assets on the balance sheet as of December 2024 : C$4.20 Billion
According to Exelixis's latest financial reports the company's total assets are C$4.20 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Exelixis - Total assets on balance sheet (from 2001 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | C$4.22 B | 8.39% |
| 2023-12-31 | C$3.90 B | -6.36% |
| 2022-12-31 | C$4.16 B | 25% |
| 2021-12-31 | C$3.33 B | 22.35% |
| 2020-12-31 | C$2.72 B | 10.66% |
| 2019-12-31 | C$2.46 B | 27.12% |
| 2018-12-31 | C$1.93 B | 135.16% |
| 2017-12-31 | C$0.82 B | 2.91% |
| 2016-12-31 | C$0.80 B | 73.65% |
| 2015-12-31 | C$0.46 B | 22.89% |
| 2014-12-31 | C$0.37 B | -29.98% |
| 2013-12-31 | C$0.53 B | -25.29% |
| 2012-12-31 | C$0.71 B | 79.25% |
| 2011-12-31 | C$0.40 B | 10.92% |
| 2010-12-31 | C$0.36 B | -0.19% |
| 2009-12-31 | C$0.36 B | -26.01% |
| 2008-12-31 | C$0.48 B | 18.78% |
| 2007-12-31 | C$0.41 B | -10.7% |
| 2006-12-31 | C$0.46 B | 18.85% |
| 2005-12-31 | C$0.38 B | 10.7% |
| 2004-12-31 | C$0.34 B | -24.61% |
| 2003-12-31 | C$0.46 B | -13.34% |
| 2002-12-31 | C$0.53 B | -3% |
| 2001-12-31 | C$0.55 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 | C$106.38 B | 2,431.50% | 🇬🇧 UK |
 | C$197.01 B | 4,588.15% | 🇫🇷 France |
 | C$166.95 B | 3,872.81% | 🇺🇸 USA |
 | C$132.02 B | 3,041.54% | 🇺🇸 USA |
 | C$130.93 B | 3,015.63% | 🇺🇸 USA |
 | C$256.77 B | 6,010.00% | 🇺🇸 USA |
 | C$304.23 B | 7,139.43% | 🇺🇸 USA |
 | C$58.83 M | -98.60% | 🇺🇸 USA |
 | C$0.14 B | -96.57% | 🇺🇸 USA |